The need for routine physical health care in schizophrenia

European Psychiatry

Volumn 25, Issue SUPPL. 2, 2010, Pages

  Montejo, A L ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Antipsychotic agents; Physical health; Schizophrenia

Indexed keywords

PROLACTIN; RECREATIONAL DRUG;

ADVERSE DRUG REACTION; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; HEALTH CARE; HEALTH HAZARD; HUMAN; HYPERPROLACTINEMIA; IMMOBILIZATION; LIFE EXPECTANCY; LONG TERM CARE; MENTAL HEALTH CARE; METABOLIC SYNDROME X; OBESITY; PATIENT COMPLIANCE; PATIENT MONITORING; PHYSICAL DISEASE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSYCHIATRIST; SCHIZOPHRENIA; SEDATION; SELF CARE; SEXUAL DYSFUNCTION; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT GAIN; WELLBEING;

ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; COOPERATIVE BEHAVIOR; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; HEALTH BEHAVIOR; HEALTH STATUS; HEALTH STATUS INDICATORS; HUMANS; INTERDISCIPLINARY COMMUNICATION; LIFE EXPECTANCY; LIFE STYLE; METABOLIC SYNDROME X; REFERRAL AND CONSULTATION; SCHIZOPHRENIA; SPAIN; SUBSTANCE-RELATED DISORDERS;

EID: 77954150108     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(10)71699-0     Document Type: Article

References (21)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
2. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596-601. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity.
3. Balkau B., Deanfield J.E., Despres J.P., Bassand J.P., Fox K.A., Smith S.C., et al. International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 2007, 116:1942-1951.
4. Basson R., Rees P., Wang R.X., Montejo A.L., Incrocci L. Sexual Function in Chronic Illness. J Sexual Medicine 2010, 7:374-388.
5. Buckley P.F., Miller dD., Singer B., Arena J., Stirewalt E.M. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005, 79:281-288.
6. Casey D.E., Haupt D.W., Newcomer J.W., Henderson D.C., Sernyak M.J., Davidson M., et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004, 65(Suppl. 7):4-18.
7. Chue P., Cheung R. The impact of weight gain associated with atypical antipsychotic use in schizophrenia. Acta Neuropsychiatrica 2004, 16:113-123.
8. Citrome L., Yeomans D. Do guidelines for severe mental illness promote physical health and well-being?. J Psychopharmacol 2005, 19:102-109.
9. De Hert M., van Winkel R., van Eyck D., Hanssens L., Wampers M., Scheen A., et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemol Ment Health 2006, 2:14.
10. Han T.S., Van Leer E.M., Seidell J.C., Lean M.E. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ 1995, 311:1401-1405.
11. Leucht S., Burkard T., Henderson J., Maj M., Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007, 116:317-333.
12. McIntyre R.S. Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey. J Clin Psychiatry 2009, 70(Suppl 3):5-11.
13. McIntyre RS, Stave C, O'Brien C, Jina AS, Chang L. UNITE = Understanding Needs, Interactions, Treatment and Expectations: a global survey of carers and patients with scizophrenia and bipolar disorder. Poster presented at the 15th Association of European Psychiatrists meeting, Madrid, Spain, 17-21 March 2007.
14. Montejo A.L. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol 2008, 18(Suppl 2):S108-S114.
15. Montejo A.L., Majadas S., Rico-Villademoros F., Llorca G., De La Gándara J., Franco M., Martín-Carrasco M., Aguera L., Prieto N. Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics. J Sexual Medicine 2010, 20214720. for the Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction, [Epub ahead of print] PMID.
16. Montejo A.L., Rico-Villademoros F. Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQSALSEX) in patients with schizophrenia and other psychotic disorders. J Sex Marital Ther 2008, 34:227-239.
17. Nasrallah H.A., Meyer J.M., Goff D.C., McEvoy J.P., Davis S.M., Stroup T.S., et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006, 86:15-22.
18. Osby U., Correia N., Brandt L., Ekbom A., Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000, 45:21-28.
19. Weiden P.J., Mackell J.A., McDonnell D.D. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004, 66:51-57.
20. Yusuf S., Hawken S., Ounpuu S., Bautista L., Franzosi M.G., Commerford P., et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005, 366:1640-1649.
21. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.